Sparsentan
- Generic Name
- Sparsentan
- Brand Names
- Filspari
- Drug Type
- Small Molecule
- Chemical Formula
- C32H40N4O5S
- CAS Number
- 254740-64-2
- Unique Ingredient Identifier
- 9242RO5URM
- Background
Sparsentan is a dual antagonist of the endothelin type A receptor (ETR) and the angiotensin II (Ang II) type 1 receptor (ATR) with a similar affinity for both (9.3 nM for ETR and 0.8 nM for ATR). Sparsentan is first in its class and orally active, and was created by merging the structural elements of irbesartan, an ATR antagonist, and biphenylsulfonamide, an...
- Indication
Sparsentan is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
- Associated Conditions
- Proteinuria
- Associated Therapies
- -
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05856760
- Locations
- 🇭🇰
Travere Investigational Site, Tsuen Wan, Hong Kong
🇺🇸Travere Investigation SIte, Clifton Park, New York, United States
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
- Conditions
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 32
- Registration Number
- NCT05630612
- Locations
- 🇬🇧
Centre for Cardiovascular Science, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh, United Kingdom
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05003986
- Locations
- 🇬🇧
Travere Investigational Site, Manchester, United Kingdom
A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 12
- Registration Number
- NCT04663204
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Trust, Cambridge, England, United Kingdom
🇬🇧Northern Care Alliance NHS Foundation Trust - Salford Royal, Salford, England, United Kingdom
🇬🇧Royal Infirmary of Edinburgh & Western General Hospital, Edinburgh, Scotland, United Kingdom
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 406
- Registration Number
- NCT03762850
- Locations
- 🇬🇧
Travere Investigational Site, London, United Kingdom
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 371
- Registration Number
- NCT03493685
- Locations
- 🇬🇧
Travere Investigational Site, York, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.